ABSTRACT
The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer and colleagues in 1961 and Barbeau and colleagues in 1962, and in its ultimately successful form by Cotzias and colleagues in 1967, still represents the defining landmark in the treatment of PD (1-3). This dramatic advance was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.
